BAY 1797

Key Product Details

Product Description

BAY 1797 is a selective purinergic P2X₄ receptor antagonist (IC₅₀ values are 108, 112 and 233 nM for the human, mouse and rat P2X₄, respectively). It is selective for P2X₄ over P2X₃, P2X₇, and P2X₁ receptors (IC₅₀ values are 8.3, 10.6 and >50 μM, respectively, for the human receptors). BAY 1797 dose-dependently reduces prostaglandin E₂ levels and exhibits anti-inflammatory and analgesic effects in an in vivo model of inflammatory pain. Orally active.

Licensing Information

This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY 1797 probe summary on the SGC website.

Product Specifications for BAY 1797

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BAY 1797

The following data is based on the product molecular weight 416.88.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.40 mL	11.99 mL	23.99 mL
5 mM	0.48 mL	2.40 mL	4.80 mL
10 mM	0.24 mL	1.20 mL	2.40 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Werner Discovery and characterization of the potent and selective P2X₄ inhibitor N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile. J.Med.Chem. 2019 PMID: 31746599

Product Documents for BAY 1797